Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
| ▸ | KIF11 | P52732 | 12/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | AGXT | P21549 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31053156 | 0.84 | CYP3A4 (0.50) | CYP3A4TSHRALDH1A1MAPK1ESR2 | |
| SCHEMBL119351 | 0.84 | CYP3A4 (0.50) | CYP3A4TSHRALDH1A1MAPK1ESR2 | |
| SCHEMBL23137319 | 0.83 | CYP3A4 (0.90) | CYP3A4TSHRALDH1A1MAPK1ESR2 | |
| SCHEMBL3903661 | 0.82 | KIF11 (0.61) | KIF11HDAC2AGXTMAOB | |
| Hydrochloric Acid SCHEMBL6862385 | 0.82 | ALDH1A1 (0.52) | CYP3A4TSHRALDH1A1MAPK1KIF11 | |
| SCHEMBL8872306 | 0.81 | CYP3A4 (0.94) | CYP3A4TSHRALDH1A1MAPK1ESR2 | |
| SCHEMBL29365311 | 0.81 | CYP3A4 (0.94) | CYP3A4TSHRALDH1A1MAPK1ESR2 | |
| SCHEMBL49382 | 0.81 | CYP3A4 (0.94) | CYP3A4TSHRALDH1A1MAPK1ESR2 | |
| Hydrochloric Acid SCHEMBL30242948 | 0.79 | CYP3A4 (1.00) | CYP3A4TSHRALDH1A1MAPK1ESR2 | |
| Hydrochloric Acid SCHEMBL864592 | 0.79 | CYP3A4 (1.00) | CYP3A4TSHRALDH1A1MAPK1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1706111-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1694281-A4 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070259951-A1 | Compounds, Compositions and Methods | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070142460-A1 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2007-06-21 | — | — | US | disclosed |
| EP-1706111-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-04 | — | — | EP | disclosed |
| EP-1694281-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005062847-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005060692-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259951-A1 | Compounds, Compositions and Methods | ALPP, PCNA, MKI67 | CYP3A4 4658/4885TSHR 4669/4885ALDH1A1 2715/4885 |
| US-20070142460-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | CYP3A4 4658/4885TSHR 4669/4885ALDH1A1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.